Equities analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce earnings of $0.10 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is $0.19 and the lowest is $0.06. Arrowhead Pharmaceuticals posted earnings of ($0.12) per share in the same quarter last year, which would indicate a positive year over year growth rate of 183.3%. The business is scheduled to report its next quarterly earnings results on Tuesday, December 10th.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of $0.73 per share for the current year, with EPS estimates ranging from $0.60 to $0.89. For the next year, analysts expect that the business will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.83) to $0.05. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.13). The firm had revenue of $42.70 million during the quarter, compared to analysts’ expectations of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%.
Shares of NASDAQ:ARWR traded down $0.75 during mid-day trading on Friday, hitting $30.14. The stock had a trading volume of 1,230,102 shares, compared to its average volume of 1,723,987. The company has a market cap of $2.93 billion, a PE ratio of -46.37 and a beta of 1.51. Arrowhead Pharmaceuticals has a 12-month low of $10.41 and a 12-month high of $36.80. The company’s 50 day moving average is $30.88 and its 200-day moving average is $24.26.
In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 85,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $30.00, for a total value of $2,550,000.00. Following the completion of the sale, the director now owns 121,000 shares in the company, valued at approximately $3,630,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael S. Perry sold 100,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $28.90, for a total transaction of $2,890,000.00. Following the completion of the sale, the director now owns 121,000 shares of the company’s stock, valued at approximately $3,496,900. The disclosure for this sale can be found here. In the last quarter, insiders sold 202,756 shares of company stock valued at $5,930,243. Insiders own 4.80% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in ARWR. Sound Income Strategies LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $34,000. Acadian Asset Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $34,000. Mascoma Wealth Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $46,000. Pearl River Capital LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $111,000. Finally, TCI Wealth Advisors Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 1,609.0% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 5,298 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 4,988 shares in the last quarter. Institutional investors own 80.11% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: How much can an individual set aside as a catch-up contribution?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.